mTOR inhibitors as a new therapeutic option for epilepsy. (Q38112211)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23739000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

mTOR inhibitors as a new therapeutic option for epilepsy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23739000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23739000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Paolo Curatolo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23739000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

1 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23739000%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23739000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23739000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23739000%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

627-638

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23739000%20AND%20SRC:MED&resulttype=core&format=json

mTOR: A pathogenic signaling pathway in developmental brain malformations

2 March 2020

cites work

1 reference

Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy

21 January 2018

1 reference

Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target

21 January 2018

1 reference

The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis

21 January 2018

1 reference

Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life

21 January 2018

1 reference

Role of mTOR in physiology and pathology of the nervous system

21 January 2018

1 reference

Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2

21 January 2018

1 reference

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders

21 January 2018

1 reference

mTOR signaling: at the crossroads of plasticity, memory and disease

21 January 2018

1 reference

Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders

21 January 2018

1 reference

PTEN: from pathology to biology

21 January 2018

1 reference

Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5.

21 January 2018

1 reference

Dysregulation of the TSC-mTOR pathway in human disease

21 January 2018

1 reference

mTOR pathway as a target in tissue hypertrophy.

21 January 2018

1 reference

De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly

21 January 2018

1 reference

Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo

21 January 2018

1 reference

Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.

21 January 2018

1 reference

Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis

21 January 2018

1 reference

Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission

21 January 2018

1 reference

The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice

21 January 2018

1 reference

Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats

21 January 2018

1 reference

Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites.

21 January 2018

1 reference

Single-channel activity of the Ca2+-dependent K+ channel is modulated by FK506 and rapamycin

21 January 2018

1 reference

A role for the mTOR pathway in surface expression of AMPA receptors.

21 January 2018

1 reference

Identification of new epilepsy treatments: issues in preclinical methodology

21 January 2018

1 reference

Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy

21 January 2018

1 reference

Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation

21 January 2018

1 reference

Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation

21 January 2018

1 reference

Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via mTOR signaling

21 January 2018

1 reference

Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis

21 January 2018

1 reference

Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy.

21 January 2018

1 reference

A pulse rapamycin therapy for infantile spasms and associated cognitive decline

21 January 2018

1 reference

Rapamycin is a neuroprotective treatment for traumatic brain injury.

21 January 2018

1 reference

Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia

21 January 2018

1 reference

mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy

21 January 2018

1 reference

The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy

21 January 2018

1 reference

Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy

21 January 2018

1 reference

Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice

21 January 2018

1 reference

Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy

21 January 2018

1 reference

Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice

21 January 2018

1 reference

Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling

21 January 2018

1 reference

Focal Cortical Dysplasias: clinical implication of neuropathological classification systems.

21 January 2018

1 reference

Characteristics of epilepsy in focal cortical dysplasia in infancy.

21 January 2018

1 reference

Focal cortical dysplasia: a genotype-phenotype analysis of polymorphisms and mutations in the TSC genes

21 January 2018

1 reference

Hamartin variants that are frequent in focal dysplasias and cortical tubers have reduced tuberin binding and aberrant subcellular distribution in vitro

21 January 2018

1 reference

Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia

21 January 2018

1 reference

Detection of human papillomavirus in human focal cortical dysplasia type IIB.

21 January 2018

1 reference

PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome

21 January 2018

1 reference

mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo

21 January 2018

1 reference

Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease

21 January 2018

1 reference

Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease

21 January 2018

1 reference

Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice

21 January 2018

1 reference

Early control of seizures improves long-term outcome in children with tuberous sclerosis complex

21 January 2018

1 reference

Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis

21 January 2018

1 reference

Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex

21 January 2018

1 reference

Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway.

21 January 2018

1 reference

Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment

21 January 2018

1 reference

Impaired synaptic plasticity in a rat model of tuberous sclerosis

21 January 2018

1 reference

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

21 January 2018

1 reference

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

21 January 2018

1 reference

Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions

21 January 2018

1 reference

Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex

21 January 2018

1 reference

Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex

21 January 2018

1 reference

Recent advances in neurobiology of Tuberous Sclerosis Complex.

21 January 2018

1 reference

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

21 January 2018

1 reference

The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway

21 January 2018

1 reference

Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation

21 January 2018

1 reference

Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex.

21 January 2018

1 reference

The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.

21 January 2018

1 reference

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

Rapamycin reduces seizure frequency in tuberous sclerosis complex

21 January 2018

1 reference

Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex.

21 January 2018

1 reference

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

21 January 2018

1 reference

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

21 January 2018

1 reference

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex

21 January 2018

1 reference

Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.

21 January 2018

1 reference

Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.

21 January 2018

1 reference

STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice

21 January 2018

1 reference

Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features

21 January 2018

1 reference

Presynaptic modulation of cortical synaptic activity by calcineurin.

21 January 2018

1 reference